Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ana Parra, Claudia Hernández & Laura Prieto-Pinto. (2023) Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-10.
Read now
Read now
Olga Delgado Sánchez, Antonio Gutiérrez, Fernando do Pazo, Jordi Ginés, Clara Martorell, Bàrbara Boyeras, Leyre Bento, Marta Garcia-Recio & Antonia Sampol. (2019) Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients. ClinicoEconomics and Outcomes Research 11, pages 695-701.
Read now
Read now
András Inotai, Tamás Ágh, Alexei Willem Karpenko, Antal Zemplényi & Zoltán Kaló. (2019) Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 105-113.
Read now
Read now
Articles from other publishers (2)
María Reyes Abad-Sazatornil, Ainhoa Arenaza, Juan Bayo, Jesus García Mata, José María Guinea De Castro, Josefa León, Javier Letellez, Virginia Reguero, Carmen Martínez Chamorro & Antonio Salar. (2021) Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study. BMC Health Services Research 21:1.
Crossref
Crossref
Konstantin Tachkov, Maria Kamusheva, Konstantin Mitov, Miglena Doneva & Guenka Petrova. (2019) Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria. Frontiers in Public Health 7.
Crossref
Crossref